GHK-Cu
Copper-binding tripeptide; epigenetic modulator of 4,000+ genes driving tissue remodeling, collagen synthesis, and antioxidant defense
Quick Facts
| Property | Value |
|---|---|
| Also Known As | Glycyl-L-Histidyl-L-Lysine Copper Complex, Copper Tripeptide-1, Prezatide Copper |
| Category | Anti-Aging / Cosmetic / Recovery |
| Sequence | GHK (Gly-His-Lys) + Cu²⁺ |
| Molecular Weight | ~405 Da (copper complex) |
| Molecular Formula | C₁₄H₂₃N₅O₄·Cu |
| PubChem CID | 73587 |
| Administration | Topical / SubQ / With Microneedling |
| Typical Dose Range | Topical: 0.05–2% cream/serum; Injectable: 1–2 mg/day SubQ |
| Half-Life | Not well characterized; copper complex is metabolized systemically |
| Storage | Lyophilized: -20°C, 2–3 years (desiccated, light-protected); Reconstituted: 2–8°C, 3–4 weeks. Degradation: blue/violet → green/yellow = discard |
| FDA Status | Topical: cosmetic ingredient (Category 1); Injectable: Research-only (Category 2) |
| WADA Status | Prohibited under S0 (Non-Approved Substances) |
Mechanism of Action
GHK-Cu is a naturally occurring copper-binding tripeptide first isolated from human plasma by Pickart in 1973. Its primary mechanism is broad genomic modulation — GHK resets the expression of over 4,000 human genes (approximately 6% of the genome), upregulating 59% (repair, antioxidant defense, stem cell maintenance) and downregulating 41% (inflammation, metastasis, tissue destruction). This was demonstrated using the Broad Institute Connectivity Map at 1 μM concentration (PMID-25302294).
At the tissue level, GHK-Cu drives ECM remodeling through a dual mechanism: simultaneously increasing collagen I/III synthesis (up to 70%), elastin, and glycosaminoglycans while upregulating MMP-2 with compensatory TIMP-1/2 increases — creating "smart remodeling" that builds new matrix while clearing damaged tissue. It acts as a chemoattractant for macrophages, mast cells, and capillary endothelial cells, and stimulates fibroblast and keratinocyte proliferation for wound repair (PMID-18644225).
GHK-Cu also provides potent antioxidant defense by delivering copper to Cu,Zn-SOD and blocking iron release from ferritin (87% reduction). It inhibits NF-κB and p38 MAPK, reducing TNF-α and IL-6. The gene expression modulation extends to neurological function — GHK resets pathological gene expression patterns associated with Alzheimer's and Parkinson's diseases toward healthier states (PMID-28212278).
A high-impact 2023 study demonstrated that plasma GHK levels are significantly decreased in COPD patients, and GHK-Cu treatment rescues smoking-induced skeletal muscle dysfunction via SIRT1 activation — linking GHK-Cu to sirtuin/longevity biology (PMID-36905132).
Key Research Areas
-
Gene Expression Modulation (4,000+ genes) — Pickart's landmark work using the Connectivity Map showed GHK resets diseased cell gene expression (cancer, COPD) toward healthier states, modulating genes involved in DNA repair, antioxidant defense, and inflammation suppression (PMID-25302294, PMID-26236730).
-
Skin Aging and Wound Healing — GHK-Cu increases collagen, elastin, and GAG synthesis. Clinical skin studies show tightening, wrinkle reduction, and improved clarity. GHK-Cu liposomes enhanced scald wound healing by 33% with accelerated angiogenesis (PMID-18644225, PMID-28370978).
-
Neuroprotection and Cognitive Decline — Gene expression analysis reveals GHK modulates patterns relevant to Alzheimer's, Parkinson's, and age-related cognitive decline through antioxidant and anti-inflammatory pathways (PMID-28212278).
-
COPD and Sarcopenia — Plasma GHK decreased in COPD patients; GHK-Cu treatment rescued smoking-induced muscle dysfunction via SIRT1 pathway (J Cachexia Sarcopenia Muscle, IF ~9.4) (PMID-36905132).
-
Pulmonary Anti-Inflammation — GHK-Cu reduced ROS, increased SOD, and decreased TNF-α/IL-6 in acute lung injury models (PMID-27517151).
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human biomarker data | 1 | COPD plasma GHK levels (PMID-36905132) |
| Animal in vivo | 3 | Wound healing, lung injury, muscle dysfunction |
| In vitro / computational | 2 | Gene expression analysis (Connectivity Map) |
| Narrative reviews | 5 | Anti-aging, skin, tissue remodeling, neuroprotection |
| Total vault studies | 11 |
The evidence base for GHK-Cu is moderate with unique genomic depth. The 4,000+ gene modulation data is unparalleled among peptides, though it relies on computational analysis rather than traditional wet-lab experiments. Human data is limited to cosmetic skin studies and one COPD biomarker study. Methodological concern: Pickart (GHK discoverer and patent holder) is first author on 4 of 11 studies — single-group concern with commercial conflict of interest.
Clinical Applications
- Anti-Aging — Epigenetic reset, collagen synthesis, antioxidant defense
- Skin Health — Wrinkle reduction, skin tightening, collagen/elastin synthesis
- Wound Healing — ECM remodeling, chemoattraction, angiogenesis
- Hair Growth — Follicle stem cell support, dermal papilla stimulation
- Post-Procedure Recovery — Post-laser, post-peel, post-microneedling recovery
- Injury Recovery — Tissue remodeling and anti-inflammatory effects
- Neuroprotection — Gene expression patterns relevant to neurodegeneration
- Sarcopenia — SIRT1-mediated muscle protection (COPD model)
Protocols Using This Peptide
- Skin Rejuvenation Protocol — Core peptide for dermatological applications
- Anti-Aging Daily Protocol — Daily anti-aging stack component
- Longevity Stack Protocol — Longevity/regenerative component
- Recovery Stack Protocol — Tissue remodeling support
- Wolverine Stack Protocol — Present in GLOW/KLOW blend variants
Ageless Peps Products
- AP-GHKCu-Vial — GHK-Cu Vial, $112 retail
- AP-GHKCu-2MG-Capsules — GHK-Cu Capsules, 2mg x 60 caps, $136 retail
- AP-GLOW-Blend — GLOW Blend (GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg), from $134 retail
- AP-KLOW-Blend — KLOW Blend (GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg + KPV 10mg), $153 retail
Dosing Reference
Research Dosing Ranges
| Route | Dose Range | Frequency | Duration | Source | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Topical | 0.05–2% cream/serum | 1–2x daily | Ongoing | PMID-25302294). The evidence is conflicting — the pro-angiogenic mechanism drives a contraindication, but the gene expression data suggests potential anti-cancer effects. Action: Avoid in active cancer until this conflict is resolved by further research.
Synergistic Combinations
Related Research
Related#peptide #anti-aging #cosmetic #recovery #subq #topical |